St. Joseph Regional Medical Center is proud to offer casirivimab and imdevimab therapy, a monoclonal antibody treatment for eligible positive COVID-19 patients.
Casirivimab and imdevimab is a monoclonal antibody therapy to help treat non-hospitalized patients with a mild or moderate case of COVID-19 (SARS-CoV-2). Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful viruses. This therapy is designed to help block the COVID-19 virus and prevent the virus from further infecting healthy cells.
Casirivimab and imdevimab have received emergency use authorization (EUA) from the Food and Drug Administration (FDA).
Adults and adolescents 12 years of age or older with mild to moderate symptoms who weigh 88 pounds (40 kg) or more, and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization.
Patients must meet specific clinical criteria including:
In addition to meeting the above criteria, patients must also have an order from a provider to receive this treatment.
This treatment WILL NOT be considered for patients who are currently hospitalized due to COVID-19, require oxygen therapy for COVID-19, and/or have a known hypersensitivity to casirivimab and imdevimab.
This therapy requires an order from a healthcare provider.
Contact your primary care physician (PCP) to make an appointment.
If you do not have a PCP, call our Provider Referral Line (PRL) at 1.888.757.DOCS (3627)
Your physician’s office will provide steps on how and where you will be receiving your treatment. Treatment is administered either by intravenous route (using IV therapy) or by subcutaneous injections. Patients receiving treatment at St. Joe’s will be required to stay for a duration of up to 2 hours.
For information on the authorized use of casirivimab and imdevimab and mandatory requirements under the Emergency Use Authorization, please review:
Fact Sheet for Patients, Parents and Caregivers (English)
Fact Sheet for Patients, Parents and Caregivers (Spanish)